Phase II study on combination of capecitabine and oxaliplatin in patients with relapsed or refractory gastric cancer

Trial Profile

Phase II study on combination of capecitabine and oxaliplatin in patients with relapsed or refractory gastric cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 25 May 2010

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov record.
    • 29 Jan 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 24 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top